Suspense over Advani's address as BJP National Executive meets in Bengaluru

April 3, 2015

Bengaluru, Apr 3: Bharatiya Janata Party's two-day national executive meet begins in the Karnataka capital on Friday, but all eyes will be on party doyen LK Advani whose name doesn't feature among the list of speakers at the event, sources said.

Advani

However, Law Minister DV Sadananda Gowda confirmed that Advani will attend the meet.

"Advani ji will come here on Friday. He is a national executive member, not an office bearer so he will come only tomorrow," he said.

Evading a direct reply to the question, party spokesperson Syed Shahnawaz Hussain said "the party has the guidance of all senior leaders".

Despite repeated questions, the BJP leader refused to say whether or not Advani would deliver a speech.

Advani, one of BJP's main founding members and tallest leaders, has attended and addressed at all national executive meetings of the party since 1980 when the party was founded, except one exception.

During the last meet in Goa when Narendra Modi was named the head of the party's campaign committee in Lok Sabha polls, not only did Advani skip the event but also sent a letter resigning from all posts of the party.

His differences with the party's decision were later reconciled and he took back his resignation. After that, Advani, more than once, has congratulated Modi for leading the BJP to victory in general elections.

According to party sources, this time Advani, a three-time BJP president, is not keen on addressing the party's national executive meet.

Sources added that organisation secretary of the party Ramlal met Advani in Delhi days before the meet over the issue. But it was not clear if Advani will speak at the forum.

Advani, along with Atal Bihari Vajpayee and Murli Manohar Joshi, is a part of a 'Margdarshak Mandal' , or the party's guiding committee which includes Narendra Modi and Rajnath Singh.

The three veterans have already been eased out of BJP's parliamentary board, the highest decision-making body of the party.

The guiding committee, however, has not held a single meet since being set up last August.

In its ts national executive meet on Friday and Saturday, the BJP will focus on expanding its base in the country, especially among states of Tamil Nadu, West Bengal, Kerala, Assam, Andhra Pradesh, Telangana and Odisha where it is weak.

BJP leaders are also likely to discuss how to involve workers in the Clean India and Clean Ganga campaigns.

The meeting, which is likely to be the last one before the Bihar assembly polls, is also expected to focus on the state elections.

Also featuring on the agenda will be BJP's poor performance in Delhi, upcoming state polls and the party's membership drive.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 11,2020

New Delhi, Feb 11: As the counting of votes for the Delhi Assembly polls began, Congress leader Digvijaya Singh on Tuesday raised doubts on EVMs, alleging that no machine having a chip is tamper-proof.

He called upon the Election Commission and the Supreme Court to take a fresh look at the use of EVMs in the country.

"No machine (which) has a chip is tamper-proof. Also please do for a moment think, why no developed country uses EVM," Singh said in a tweet.

"Would CEC and Hon Supreme Court please have a fresh look on EVM voting in India? We are the largest democracy in the world, we can't allow some unscrupulous people to hack results and steal the mandate of 1.3 billion people.

"If they match the votes in the counting unit. Declare the result. If they don't match then count the ballots of all polling booths in the assembly. It would convince everyone and save time also as this has been the consistent argument of CEC in favour of EVM," the Congress leader said.

Polling for the 70-member Delhi Assembly polls was held on Saturday.

The Election Commission on Sunday announced that the final voter turnout was 62.59 per cent, five per cent less than 2015.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 19,2020

New Delhi, Mar 19: Former Chief Justice of India Ranjan Gogoi took oath as Rajya Sabha MP on Thursday.

Gogoi's wife Rupanjali Gogoi, daughter, and son in law were also present in Parliament.

Congress staged a walkout from the Rajya Sabha over Gogoi's membership to the House.

Meanwhile, Union Minister Ravishankar Prasad welcomed Gogoi in the Rajya Sabha.

President Ram Nath Kovind had nominated the former CJI to the Rajya Sabha on March 16.

Gogoi served as the 46th Chief Justice of India from October 3, 2018, to November 17, 2019.

On November 9, 2019, a five-judge Bench headed by him had delivered the verdict in the long-pending Ramjanmabhoomi case.

Comments

Fairman
 - 
Thursday, 19 Mar 2020

People lost trust in Judiciary because of such horrible criminals.

 

He betrayed the whole nation. Unless he is booked, the judiciary will not restore the lost faith. 

 

 

The loss may be momentary in nature, It is the promise of the Almighty, He will ensure the justice is served to everyone. 

 

Angry Indian
 - 
Thursday, 19 Mar 2020

Pure slave like goo mutur....nice life DDDDOOOOGGGGG

 

ayes p.
 - 
Thursday, 19 Mar 2020

Fixed from judgement of babri masjid to rajya sabha member

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 25,2020

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.